KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: commercial-stage wearable medical device and digital healthcare company focused on cardiovascular patient monitoring and therapy via the Cardiac Recovery System platform anchored by the ASSURE WCD
• • New product emphasis: April 2026 launch of Enhanced ASSURE Detection Algorithm improving rhythm discrimination and reducing false alarms to estimated 3% from prior 6%
• • Strategic shift: plans to expand internationally with CE Mark pursuit targeting Western Europe within three years, marking first regulatory approval efforts outside the U.S.
• • Quantitative metric: commercial protection of nearly 40,000 patients by April 2026 and enrollment of ~40,000 patients in ongoing ASSURE Patient Registry
• • Noteworthy fact: strategic collaboration in January 2026 with Biobeat Technologies to integrate FDA-cleared cuffless ambulatory blood pressure monitoring into product portfolio

Risk Factors

• • Regulatory risk: Ongoing enforcement and compliance scrutiny by DOJ, HHS OIG, state attorneys general, and CMS around financial relationships with healthcare providers and billing practices
• • Macroeconomic threat: Inflation and inflation-driven cost increases for materials, labor, shipping, and component shortages may raise manufacturing expenses and reduce profitability
• • Operational vulnerability: Reliance on limited suppliers for ASSURE WCD components, with no large inventory; delays in component supply or device reconditioning by third-party manufacturers risk product shortages
• • Competitive risk: Primary competitor ZOLL Medical (Asahi Kasei subsidiary) and a new FDA-approved adhesive-based external defibrillator competitor threaten market share
• • Financial risk: $45 million Term Loan with collateral on all assets and restrictive covenants limits operational flexibility and requires substantial quarterly interest payments

Management Discussion & Analysis

• • Revenue $95.1M, up 59% YoY from $59.8M in 2025, driven by 58% patient growth
• • Gross profit $48.9M (51.4% margin) vs $24.2M (40.5% margin) in 2025; gross profit margin increased ~11pp
• • Best segment: Leasing of ASSURE WCD with revenue $95.1M; no separate segments disclosed
• • Operating loss widened to $134.7M from $106.4M; R&D increased 24% to $19.5M, SG&A up 43% to $164.1M
• • Cash flow: Operating cash outflow $81.7M; investing cash outflow $203.3M; financing cash inflow $147.1M including $149.3M secondary offering
• • Capital allocation: Raised $149.3M in Dec 2025 offering; invested $34.9M in property/equipment; no buybacks/dividends reported
• • Outlook: Existing cash $262.2M sufficient for 12+ months; risk of needing future funding if costs rise or cash from operations lags

What are the latest KMTS SEC filings in 2026?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has filed a 10-K annual report on July 14, 2026, a 10-Q quarterly report on March 17, 2026, an 8-K current report on July 14, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did KMTS file its most recent 10-K annual report?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed its most recent 10-K annual report on July 14, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view KMTS 10-Q quarterly reports?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)'s most recent 10-Q quarterly report was filed on March 17, 2026. SignalX displays every KMTS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has KMTS filed recently?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)'s most recent 8-K was filed on July 14, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find KMTS insider trading activity (Form 4)?

SignalX aggregates every KMTS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does KMTS file with the SEC?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KMTS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

What is KMTS's SEC CIK number?

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)'s SEC CIK (Central Index Key) number is 1877184. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1877184 to look up all KMTS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find KMTS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.